Zhejiang Medicine Co., Ltd.

600216

CNE0000010J2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 27/05/2024 am IST			5-day change	1st Jan Change
10.18 ^CNY	+0.30%		-4.23%	-5.13%

25/04	Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
2023	Zhejiang Medicine Wins Nod to Trial Digestive Acid Drug	MT

Zhejiang Medicine Co., Ltd. Announces Taxes Included Cash Dividend for the Full Year Ended on December 31, 2019, Payable on June 29, 2020

June 18, 2020

Zhejiang Medicine Co., Ltd. announced a taxes included cash dividend of RMB 10 per 10 shares full year ended of December 31, 2019. The cash dividend payable on June 29, 2020, record date is June 24, 2020. Ex-dividend date is June 29, 2020.

Latest news about Zhejiang Medicine Co., Ltd.

Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Zhejiang Medicine Wins Nod to Trial Digestive Acid Drug	28/11	MT
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	25/23/25	CI
Zhejiang Medicine Wins Nod to Trial Anti-Tumor Drug	19/23/19	MT
Zhejiang Medicine’s South Korean Unit Clears Good Manufacturing Practice Inspection	23/23/23	MT
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23/23/23	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	25/23/25	CI
Citic Securities says global financial market fluctuations hurt business	31/23/31	RE
Zhejiang Medicine to Market Antibiotic in the US After Getting FDA Nod; Shares Jump 3%	30/23/30	MT
Zhejiang Medicine Co., Ltd.(SHSE:600216) dropped from Shanghai Stock Exchange Health Care Sector Index	09/22/09	CI
Zhejiang Medicine Unit Gets Clinical Trial Approval For Anti-Biliary Tract Cancer Drug	01/22/01	MT
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	26/22/26	CI
Brokerage CLSA vice-chairman Charles Lin resigns	26/22/26	RE
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25	CI
Zhejiang Medicine Co., Ltd.(SHSE:600216) added to Shanghai Stock Exchange Health Care Sector Index	13/22/13	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/22/26	CI
TaiGen Biopharmaceuticals Turns to Profit in 2021	17/22/17	MT
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	25/21/25	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	25/21/25	CI
Zhejiang Medicine Co., Ltd.(SHSE:600216) dropped from Shanghai Stock Exchange Health Care Sector Index	11/21/11	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	22/21/22	CI
Zhejiang Health Creation Bio-Technology Co., Ltd. announced that it expects to receive funding from Zhejiang Medicine Co., Ltd.	27/20/27	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	22/20/22	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	25/20/25	CI

Chart Zhejiang Medicine Co., Ltd.

Duration

Period

More charts

Company Profile

Zhejiang Medicine Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of drugs and nourishments. The Company mainly provides nourishments for animals and human, health care products, and chemicals and chemical raw materials, among others. The Company's products include synthetic vitamin E, natural vitamin E soft capsules, Beta carotene, vancomycin hydrochloride for injection and teicoplanin for injection, among others. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

23/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Medicine Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.18 CNY

Average target price

11 CNY

Spread / Average Target

+8.06%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG MEDICINE CO., LTD.	-5.13%	134.28Cr
ELI LILLY AND COMPANY	+38.51%	73TCr
NOVO NORDISK A/S	+31.74%	60TCr
JOHNSON & JOHNSON	-6.23%	35TCr
MERCK & CO., INC.	+18.78%	33TCr
ABBVIE INC.	+1.35%	28TCr
ASTRAZENECA PLC	+16.00%	24TCr
NOVARTIS AG	+8.44%	20TCr
ROCHE HOLDING AG	-5.97%	20TCr
AMGEN INC.	+6.19%	16TCr

Other Pharmaceuticals